HF
ALGS icon

HRT Financial’s Aligos Therapeutics ALGS Stock Holding History

HRT Financial’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,374
Closed -$106K – 3718
2025
Q4 		$106K Buy
+11,374
New +$107K ﹤0.01% 2780
2023
Q3 		– Sell
-404
Closed -$9K – 2344
2023
Q2 		$9K Sell
404
-647
-62% -$17.4K ﹤0.01% 2179
2023
Q1 		$22K Sell
1,051
-1,599
-60% -$61.1K ﹤0.01% 2175
2022
Q4 		$63K Sell
2,650
-1,421
-35% -$35.8K ﹤0.01% 2105
2022
Q3 		$111K Sell
4,071
-1,392
-25% -$46.2K ﹤0.01% 2368
2022
Q2 		$165K Buy
5,463
+2,447
+81% +$83.1K ﹤0.01% 2304
2022
Q1 		$162K Buy
3,016
+2,464
+446% +$197K ﹤0.01% 2543
2021
Q4 		$163K Buy
+552
New +$201K ﹤0.01% 2608

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.2B AUM 41.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

HRT Financial's ALGS Position: Q1 2026 in Review

HRT Financial sold out of Aligos Therapeutics (ALGS) in Q1 2026, closing a stake of 11,374 shares — an estimated $106K sold.

HRT Financial first reported a position in ALGS in Q4 2021 and held it in 8 quarters. The position peaked at $165K in Q2 2022. 35 funds tracked by Wall St. Rank hold ALGS as of Q1 2026.

  • HRT Financial reported no remaining Aligos Therapeutics position as of Q1 2026 after selling out during the quarter.
  • HRT Financial sold 11,374 Aligos Therapeutics shares in Q1 2026, an estimated $106K.
  • HRT Financial first reported a position in Aligos Therapeutics in Q4 2021 and held it in 8 quarters.
  • HRT Financial's Aligos Therapeutics position peaked at $165K in Q2 2022.
  • 35 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.